The function and efficacy of Osimertinib
Osimertinib is a third-generation EGFR-TKI targeted drug that selectively inhibits EGFR mutations (including T790M) to block tumor signaling pathways. It is mainly used for the treatment of EGFR mutation positive non-small cell lung cancer and has precise anti-tumor effects. It has been included in medical insurance.
1. Core mechanism of action
(1) Targeted inhibition: Specifically binds to EGFR mutant proteins (including exon 19 deletion, L858R, and T790M mutations), blocking tyrosine kinase activity.
(2) Signal blockade: interferes with the downstream signaling pathway of EGFR required for tumor cell proliferation and survival.
2. Main therapeutic effects
(1) Adjuvant therapy: Used for postoperative adjuvant therapy of EGFR mutation positive non-small cell lung cancer to reduce the risk of recurrence.
(2) Late stage treatment: shows significant survival benefits for patients with locally advanced/metastatic EGFR mutant NSCLC.
(3) Resistance reversal: Effective for EGFR-TKI resistant patients caused by T790M mutation.
3. Formulation characteristics
(1) Oral tablets: oval shaped film coated tablets, convenient for patients to take.
(2) Metabolic characteristics: Metabolized by liver CYP3A enzyme, attention should be paid to drug interactions.
Disclaimer：《The function and efficacy of Osimertinib》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！